TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07127978: A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

Sponsor: ITF Therapeutics LLC · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 300 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07127978 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07127978 Rescue Dossier →